MAXWELLIA

Maxwellia is a pioneering British start-up in the biopharma, health care, and pharmaceutical industries. Founded in 2013, Maxwellia's unique proposition lies in converting prescription medicines into versions available for purchase in pharmacies. The company's dedication to facilitating the safe supply of medicines under the supervision of pharmacists sets it apart. Their innovative approach aims to alleviate the burden on general practitioners by enabling individuals to manage certain conditions without the need for a doctor's appointment. With a vision to widen access to a range of widely used and effective medicines, Maxwellia's mission revolves around making these products conveniently available in local pharmacies, thus reducing the strain on an over-stretched NHS. The latest Venture Round investment in Maxwellia occurred on October 6, 2021, and the investors behind this funding round are not specified. As Maxwellia continues to innovate and develop breakthrough products, its impact in transforming the accessibility of healthcare products and services will be one to watch.